We therefore designed this study to investigate whether the NTCP p.Ser267Phe variant exerts an additive anti-HBV effect in chronic hepatitis B (CHB) patients on mainstream NAs treatment. The gene discussed is SLC10A1; the disease is chronic hepatitis B virus infection.